Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
Identifieur interne : 001E27 ( PubMed/Corpus ); précédent : 001E26; suivant : 001E28Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
Auteurs : In Gul Kim ; Ji Youl Lee ; David S. Lee ; Jeong Yi Kwon ; Ji Hye HwangSource :
- Journal of vascular research [ 1423-0135 ] ; 2013.
English descriptors
- KwdEn :
- Animals, Combined Modality Therapy, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Implants, Female, Gelatin, Gene Expression Regulation (drug effects), High-Energy Shock Waves (therapeutic use), Hindlimb, Hydrogels, Lymphangiogenesis (drug effects), Lymphatic Vessels (drug effects), Lymphatic Vessels (injuries), Lymphatic Vessels (physiology), Lymphedema (drug therapy), Lymphedema (therapy), Macrophage Activation (drug effects), Mice, Mice, Inbred BALB C, Regeneration (drug effects), Vascular Endothelial Growth Factor C (administration & dosage), Vascular Endothelial Growth Factor C (biosynthesis), Vascular Endothelial Growth Factor C (genetics), Vascular Endothelial Growth Factor C (therapeutic use), Vascular Endothelial Growth Factor Receptor-3 (biosynthesis), Vascular Endothelial Growth Factor Receptor-3 (genetics), Wound Healing (drug effects), Wound Healing (physiology).
- MESH :
- chemical , administration & dosage : Vascular Endothelial Growth Factor C.
- chemical , biosynthesis : Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor Receptor-3.
- chemical , genetics : Vascular Endothelial Growth Factor C, Vascular Endothelial Growth Factor Receptor-3.
- chemical , therapeutic use : Vascular Endothelial Growth Factor C.
- chemical : Drug Implants, Gelatin, Hydrogels.
- drug effects : Gene Expression Regulation, Lymphangiogenesis, Lymphatic Vessels, Macrophage Activation, Regeneration, Wound Healing.
- drug therapy : Lymphedema.
- injuries : Lymphatic Vessels.
- physiology : Lymphatic Vessels, Wound Healing.
- therapeutic use : High-Energy Shock Waves.
- therapy : Lymphedema.
- Animals, Combined Modality Therapy, Disease Models, Animal, Drug Evaluation, Preclinical, Female, Hindlimb, Mice, Mice, Inbred BALB C.
Abstract
Lymphedema is a clinically incurable disease that occurs commonly after lymph node dissection and/or irradiation. Several studies have recently demonstrated that extracorporeal shock wave therapy (ESWT) could promote lymphangiogenesis associated with expression of vascular endothelial growth factor (VEGF)-C. This research concerned primarily the synergistic effect of ESWT combined with VEGF-C incorporated hydrogel (VEGF-C hydrogel) combination therapy for promoting lymphangiogenesis and ultimately alleviating lymphedema.
DOI: 10.1159/000343699
PubMed: 23208012
Links to Exploration step
pubmed:23208012Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.</title><author><name sortKey="Kim, In Gul" sort="Kim, In Gul" uniqKey="Kim I" first="In Gul" last="Kim">In Gul Kim</name><affiliation><nlm:affiliation>Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Ji Youl" sort="Lee, Ji Youl" uniqKey="Lee J" first="Ji Youl" last="Lee">Ji Youl Lee</name></author><author><name sortKey="Lee, David S" sort="Lee, David S" uniqKey="Lee D" first="David S" last="Lee">David S. Lee</name></author><author><name sortKey="Kwon, Jeong Yi" sort="Kwon, Jeong Yi" uniqKey="Kwon J" first="Jeong Yi" last="Kwon">Jeong Yi Kwon</name></author><author><name sortKey="Hwang, Ji Hye" sort="Hwang, Ji Hye" uniqKey="Hwang J" first="Ji Hye" last="Hwang">Ji Hye Hwang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23208012</idno><idno type="pmid">23208012</idno><idno type="doi">10.1159/000343699</idno><idno type="wicri:Area/PubMed/Corpus">001E27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E27</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.</title><author><name sortKey="Kim, In Gul" sort="Kim, In Gul" uniqKey="Kim I" first="In Gul" last="Kim">In Gul Kim</name><affiliation><nlm:affiliation>Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Lee, Ji Youl" sort="Lee, Ji Youl" uniqKey="Lee J" first="Ji Youl" last="Lee">Ji Youl Lee</name></author><author><name sortKey="Lee, David S" sort="Lee, David S" uniqKey="Lee D" first="David S" last="Lee">David S. Lee</name></author><author><name sortKey="Kwon, Jeong Yi" sort="Kwon, Jeong Yi" uniqKey="Kwon J" first="Jeong Yi" last="Kwon">Jeong Yi Kwon</name></author><author><name sortKey="Hwang, Ji Hye" sort="Hwang, Ji Hye" uniqKey="Hwang J" first="Ji Hye" last="Hwang">Ji Hye Hwang</name></author></analytic><series><title level="j">Journal of vascular research</title><idno type="eISSN">1423-0135</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Combined Modality Therapy</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Drug Implants</term><term>Female</term><term>Gelatin</term><term>Gene Expression Regulation (drug effects)</term><term>High-Energy Shock Waves (therapeutic use)</term><term>Hindlimb</term><term>Hydrogels</term><term>Lymphangiogenesis (drug effects)</term><term>Lymphatic Vessels (drug effects)</term><term>Lymphatic Vessels (injuries)</term><term>Lymphatic Vessels (physiology)</term><term>Lymphedema (drug therapy)</term><term>Lymphedema (therapy)</term><term>Macrophage Activation (drug effects)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Regeneration (drug effects)</term><term>Vascular Endothelial Growth Factor C (administration & dosage)</term><term>Vascular Endothelial Growth Factor C (biosynthesis)</term><term>Vascular Endothelial Growth Factor C (genetics)</term><term>Vascular Endothelial Growth Factor C (therapeutic use)</term><term>Vascular Endothelial Growth Factor Receptor-3 (biosynthesis)</term><term>Vascular Endothelial Growth Factor Receptor-3 (genetics)</term><term>Wound Healing (drug effects)</term><term>Wound Healing (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term><term>Vascular Endothelial Growth Factor Receptor-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term><term>Vascular Endothelial Growth Factor Receptor-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Vascular Endothelial Growth Factor C</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Implants</term><term>Gelatin</term><term>Hydrogels</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Gene Expression Regulation</term><term>Lymphangiogenesis</term><term>Lymphatic Vessels</term><term>Macrophage Activation</term><term>Regeneration</term><term>Wound Healing</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" qualifier="injuries" xml:lang="en"><term>Lymphatic Vessels</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Lymphatic Vessels</term><term>Wound Healing</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>High-Energy Shock Waves</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lymphedema</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Combined Modality Therapy</term><term>Disease Models, Animal</term><term>Drug Evaluation, Preclinical</term><term>Female</term><term>Hindlimb</term><term>Mice</term><term>Mice, Inbred BALB C</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lymphedema is a clinically incurable disease that occurs commonly after lymph node dissection and/or irradiation. Several studies have recently demonstrated that extracorporeal shock wave therapy (ESWT) could promote lymphangiogenesis associated with expression of vascular endothelial growth factor (VEGF)-C. This research concerned primarily the synergistic effect of ESWT combined with VEGF-C incorporated hydrogel (VEGF-C hydrogel) combination therapy for promoting lymphangiogenesis and ultimately alleviating lymphedema.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23208012</PMID><DateCreated><Year>2013</Year><Month>02</Month><Day>22</Day></DateCreated><DateCompleted><Year>2013</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0135</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Journal of vascular research</Title><ISOAbbreviation>J. Vasc. Res.</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.</ArticleTitle><Pagination><MedlinePgn>124-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000343699</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Lymphedema is a clinically incurable disease that occurs commonly after lymph node dissection and/or irradiation. Several studies have recently demonstrated that extracorporeal shock wave therapy (ESWT) could promote lymphangiogenesis associated with expression of vascular endothelial growth factor (VEGF)-C. This research concerned primarily the synergistic effect of ESWT combined with VEGF-C incorporated hydrogel (VEGF-C hydrogel) combination therapy for promoting lymphangiogenesis and ultimately alleviating lymphedema.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The VEGF-C hydrogel was applied to the injury site in a mouse model of lymphedema and then regularly underwent ESWT (0.05 mJ/mm(2), 500 shots) every 3 days for 4 weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four weeks after the treatment, mice treated with VEGF-C hydrogel and ESWT showed signs of the greatest decrease in edema/collagenous deposits when compared with the other experimental group. LYVE-1-positive vessels also revealed that the VEGF-C/ESWT group had significantly induced the growth of new lymphatic vessels compared to the other groups. Western blot analysis showed that expression of VEGF-C (1.24-fold) and VEGF receptor-3 (1.41-fold) was significantly increased in the VEGF-C/ESWT group compared to the normal group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggested that VEGF-C and ESWT had a synergistic effect and were very effective in alleviating the symptoms of lymphedema and promoting lymphangiogenesis.</AbstractText><CopyrightInformation>Copyright © 2012 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>In Gul</ForeName><Initials>IG</Initials><AffiliationInfo><Affiliation>Department of Urology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Youl</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Jeong Yi</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Ji Hye</ForeName><Initials>JH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Vasc Res</MedlineTA><NlmUniqueID>9206092</NlmUniqueID><ISSNLinking>1018-1172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004343">Drug Implants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020100">Hydrogels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C467483">vascular endothelial growth factor C, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>9000-70-8</RegistryNumber><NameOfSubstance UI="D005780">Gelatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D040321">Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004343" MajorTopicYN="N">Drug Implants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005780" MajorTopicYN="N">Gelatin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019220" MajorTopicYN="N">High-Energy Shock Waves</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006614" MajorTopicYN="N">Hindlimb</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020100" MajorTopicYN="N">Hydrogels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042583" MajorTopicYN="N">Lymphangiogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042601" MajorTopicYN="N">Lymphatic Vessels</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000293" MajorTopicYN="N">injuries</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008262" MajorTopicYN="N">Macrophage Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040321" MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23208012</ArticleId><ArticleId IdType="pii">000343699</ArticleId><ArticleId IdType="doi">10.1159/000343699</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23208012
|texte= Extracorporeal shock wave therapy combined with vascular endothelial growth factor-C hydrogel for lymphangiogenesis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23208012" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |